Editas Medicine, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Editas Medicine, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $31.94M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $13.73M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $6.05M | Mar 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.52M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $32.31M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $78.12M | Mar 5, 2025 |
| FY2024 | Dec 31, 2022 | $19.71M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $25.54M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $11.42M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $62.84M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $10.75M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $5.72M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $12.28M | Feb 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($160.06M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($237.09M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($153.22M) | Mar 5, 2025 |
| FY2024 | Dec 31, 2022 | ($220.43M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | ($192.50M) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | ($62.50M) | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $7.82M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | ($23.57M) | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | ($37.72M) | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | ($37.77M) | Feb 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($160.01M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($251.15M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($169.18M) | Mar 5, 2025 |
| FY2024 | Dec 31, 2022 | ($225.95M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | ($193.15M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($134.84M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($140.92M) | Feb 24, 2022 |
| FY2018 | Dec 31, 2018 | ($26.25M) | Mar 1, 2019 |
| FY2019 | Dec 31, 2017 | ($119.93M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | ($97.19M) | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.95M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $199.25M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $177.65M | Mar 5, 2025 |
| FY2024 | Dec 31, 2022 | $174.96M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $142.51M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $158.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $96.90M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $90.65M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $83.16M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $56.98M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($165.24M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($210.28M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($132.18M) | Mar 5, 2025 |
| FY2024 | Dec 31, 2022 | ($177.35M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | ($163.80M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($179.84M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($40.67M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($45.71M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($9.42M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | ($50.25M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $607.0K | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $8.83M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $4.72M | Mar 5, 2025 |
| FY2024 | Dec 31, 2022 | $4.12M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $7.98M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $7.16M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $6.17M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $4.75M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $2.06M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $3.49M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.53M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $341.59M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $499.15M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $514.32M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $677.48M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $572.60M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $508.89M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $420.39M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $373.26M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $229.18M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $159.25M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $207.32M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $150.06M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $153.64M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $123.84M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $179.02M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $246.45M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $184.22M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $165.18M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $94.58M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.29M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $134.27M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $349.10M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $360.68M | Mar 5, 2025 |
| FY2024 | Dec 31, 2021 | $553.64M | Mar 5, 2025 |
| FY2023 | Dec 31, 2020 | $393.59M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $262.44M | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | $236.16M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $208.08M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $134.61M | Feb 26, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.63B) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($1.47B) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($1.23B) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($1.08B) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($857.70M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | ($665.20M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($549.22M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($416.28M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($305.85M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($185.53M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.65M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $131.54M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $123.65M | Mar 5, 2025 |
| FY2024 | Dec 31, 2022 | $141.52M | Mar 5, 2025 |
| FY2022 | Dec 31, 2021 | $203.52M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $139.68M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $238.18M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $134.78M | Feb 26, 2020 |
| FY2019 | Dec 31, 2017 | $146.63M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $185.32M | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $57.43M | Mar 5, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 5, 2025 |
| FY2024 | Dec 31, 2022 | (3) | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 26, 2021 |
| FY2021 | Dec 31, 2019 | (2) | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 5, 2025 |
| FY2024 | Dec 31, 2022 | (3) | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 26, 2021 |
| FY2021 | Dec 31, 2019 | (2) | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 97.87M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 82.73M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 81.77M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 68.85M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 68.44M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 62.56M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 54.36M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 48.76M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 44.51M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 35.82M | Mar 8, 2018 |